Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 10.3% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a clinical-stage biopharmaceutical company utilizing CRISPR gene editing to develop treatments for severe diseases. The stock has shown strong market leadership with a jump in its Relative Strength (RS) Rating and has experienced significant growth over the past three months.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 10.3% on Apr 24, 2026 13:55

• The bearish movement in NTLA stock today could be attributed to the following factors:
• Despite the recent positive momentum and market leadership demonstrated by Intellia Therapeutics, investors might be taking profits after a significant 20% increase in the stock price over the past three months.
• The mixed short-term returns and recent share price volatility, coupled with potential risks such as disappointing trial results or payer pushback on costs, could be causing some uncertainty among investors.
• While analysts have provided a moderate buy rating and set an average price target of $21.25, the discrepancy between the current share price and the estimated fair value according to a DCF model might be contributing to the downward pressure on the stock.
• Investors may also be cautious due to the company's amendment of its by-laws and the designation of federal district courts as the exclusive forum for Securities Act claims, which could introduce legal uncertainties impacting the stock's performance.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia Therapeutics Shows Market Leadership With Jump To 84 RS Rating

Intellia Therapeutics (NTLA) has demonstrated market leadership by achieving an 84 Relative Strength (RS) Rating, a significant jump from its previous 79. This rating, provided by Investor's Business Daily, highlights stocks with strong price performance, indicating the company's solid position in the market. The increase in its RS Rating underscores Intellia Therapeutics' positive momentum and potential as a leading stock.

https://www.investors.com/ibd-data-stories/intellia-therapeutics-shows-market-leadership-with-jump-to-84-rs-rating/

NTLA stock rises 20% in 3 months: Here's what you should know

The NTLA stock has seen a significant 20% increase over the past three months. This article aims to provide key information and insights regarding this performance, helping investors and interested parties understand the factors contributing to its recent growth.

https://www.msn.com/en-us/health/other/ntla-stock-rises-20-in-3-months-heres-what-you-should-know/ar-AA2131vy?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

Intellia Therapeutics, Inc. (NTLA) Sees Moderate Buy Rating From Analysts

Intellia Therapeutics, Inc. (NASDAQ: NTLA) has received a moderate buy rating from Wall Street analysts, with an average price target of $21.25, following an 88.76% stock increase over the last year. The company recently amended its by-laws to allow shareholders to rectify deficiencies in timely notices and designated federal district courts as the exclusive forum for Securities Act claims. Intellia Therapeutics is a clinical-stage biopharmaceutical company utilizing CRISPR gene editing to develop treatments for severe diseases.

https://www.insidermonkey.com/blog/intellia-therapeutics-inc-ntla-sees-moderate-buy-rating-from-analysts-1743237/

A Look At Intellia Therapeutics (NTLA) Valuation After Recent Share Price Volatility

Intellia Therapeutics (NTLA) has experienced mixed short-term returns but strong year-to-date and one-year performance. Despite a recent share price of US$14.16, analysts estimate a target price of US$25, and Simply Wall St's DCF model suggests a fair value of US$150.49. The company's valuation is driven by a narrative of rapid revenue growth and expanding addressable markets, though potential risks from trial disappointments or payer pushback exist.

https://www.sahmcapital.com/news/content/a-look-at-intellia-therapeutics-ntla-valuation-after-recent-share-price-volatility-2026-04-17

A Look At Intellia Therapeutics (NTLA) Valuation After Recent Share Price Volatility

Intellia Therapeutics (NTLA) has seen recent share price volatility, closing at US$14.16, with mixed short-term returns but strong year-to-date and one-year performance. Despite trading below analyst price targets and a significantly higher intrinsic value according to Simply Wall St's DCF model, the market's current valuation remains a point of interest for investors. The article explores how demographics and genetic conditions support Intellia's value, but highlights risks such as disappointing trial results or payer pushback on costs.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/a-look-at-intellia-therapeutics-ntla-valuation-after-recent

Trending Today

Intellia Therapeutics, Inc. Price History

31.02.2026 - NTLA Stock was up 5.2%

• Despite receiving a "Hold" rating from most brokerages, Intellia Therapeutics experienced a significant uptrend after being upgraded to a "strong-buy" by Truist Financial.
• The gene editing sector, including Intellia Therapeutics, faced a downtrend, possibly influencing the stock price initially.
• Intellia Therapeutics' recent strong earnings report, surpassing expectations, likely boosted investor confidence in its performance.
• The internal reshuffling of Vanguard's holdings, resulting in share disaggregation, may have caused some uncertainty but did not have a direct impact on the stock movement.

22.03.2026 - NTLA Stock was up 6.6%

• Analysts have given NTLA a moderate buy rating with an average price target of $21.25, indicating positive sentiment towards the company's future prospects.
• Despite recent share price volatility, the company's strong year-to-date and one-year performance, along with a narrative of rapid revenue growth, have contributed to the bullish movement.
• The market's interest in NTLA's valuation, driven by demographics and genetic conditions supporting its value, coupled with potential risks from trial disappointments or payer pushback, may have influenced the positive market sentiment.
• The amendment of by-laws and designation of federal district courts as the exclusive forum for Securities Act claims could also be seen as a positive development, enhancing shareholder rights and potentially boosting investor confidence in the stock.

05.02.2026 - NTLA Stock was down 5.1%

• The bearish movement in NTLA stock today could be attributed to profit-taking by investors after a recent surge in the stock price.
• Actions impacting GLP-1 compounders by the FDA might have raised concerns about regulatory scrutiny in the biotech sector, negatively affecting NTLA's stock.
• Despite positive clinical news and increased stake by Vanguard Group Inc., the overall market sentiment towards biotech companies like Intellia might have been affected by the uncertainty surrounding FDA actions and regulatory compliance.
• Insider sales at Intellia, the company's pre-revenue status, and negative margins could have also contributed to the bearish sentiment among investors.

05.02.2026 - NTLA Stock was down 5.1%

• Despite recent positive developments, such as analyst upgrades, strong financial results, and progress with its Phase 3 trial after regulatory hurdles were resolved, Intellia Therapeutics saw a decline in its stock price.
• The market response may have been influenced by the company's decision to expand its At-The-Market offering program to $1.04 billion, which could potentially lead to dilution of existing shares and impact shareholder value.
• Concerns regarding the company's financial performance, such as negative margins and a high valuation, despite advancements in its pipeline and clinical work, might have unsettled investors.
• The divergence in opinions among analysts and the uncertainty surrounding Intellia's path to profitability likely contributed to the negative market sentiment, even amidst positive strides in its therapeutic initiatives.

03.02.2026 - NTLA Stock was down 5.1%

• The stock price of Intellia Therapeutics plummeted despite recent positive developments and analyst upgrades, indicating a possible case of "buy the rumor, sell the news" behavior among investors.
• The FDA's decision to lift the clinical hold on the MAGNITUDE Phase 3 trial for a key therapy was initially seen as a positive development, but concerns over the safety and efficacy of the treatment may have led to the market's negative reaction.
• The company's decision to increase its At-The-Market offering program to $1.04 billion could have also contributed to the bearish sentiment, signaling potential dilution of existing shares and impacting shareholder value.
• Overall, the market movement suggests that investors may be exercising caution and reevaluating their positions in Intellia Therapeutics amidst a mix of positive news and financial decisions by the company.

19.02.2026 - NTLA Stock was down 5.4%

• Farallon Capital Management LLC acquired a significant number of shares in NTLA, indicating confidence in the company's potential.
• Despite reporting better-than-expected earnings and surpassing analyst revenue estimates, company insiders have been selling shares in the last ninety days.
• The increased holdings by institutional investors may have contributed to the downward pressure on NTLA's stock price.
• The bearish movement could be a result of profit-taking by insiders or concerns about the sustainability of NTLA's recent positive performance.

21.03.2026 - NTLA Stock was up 6.2%

• NTLA stock saw a positive trend today, possibly influenced by its strong year-to-date and one-year performance, as well as favorable analyst target prices and valuation models.
• The market shows confidence in NTLA's potential for revenue growth and its capacity to meet the increasing demand for genetic therapies.
• Despite risks like disappointing trial outcomes or cost challenges, investors are currently drawn to NTLA because of its promising future and valuation indicators.

25.02.2026 - NTLA Stock was up 5.3%

• The rise in NTLA's stock price might be due to positive sentiment from AI models suggesting short-term strength and the adoption of potential institutional trading strategies.
• Despite recent selling by Hudson Bay Capital Management LP and company insiders, the stock surpassed Q3 revenue and EPS estimates, indicating solid fundamentals.
• A possible securities class action lawsuit alleging lack of disclosure on the inefficiency of the NTLA-3001 program initially led to a stock price decline, but investors appear hopeful about the company's future prospects.
• In summary, the surge in Intellia Therapeutics' stock price today could be driven by a blend of positive sentiment, exceeding financial expectations, and potential institutional trading strategies.

24.03.2026 - NTLA Stock was down 10.3%

• The bearish movement in NTLA stock today could be attributed to the following factors:
• Despite the recent positive momentum and market leadership demonstrated by Intellia Therapeutics, investors might be taking profits after a significant 20% increase in the stock price over the past three months.
• The mixed short-term returns and recent share price volatility, coupled with potential risks such as disappointing trial results or payer pushback on costs, could be causing some uncertainty among investors.
• While analysts have provided a moderate buy rating and set an average price target of $21.25, the discrepancy between the current share price and the estimated fair value according to a DCF model might be contributing to the downward pressure on the stock.
• Investors may also be cautious due to the company's amendment of its by-laws and the designation of federal district courts as the exclusive forum for Securities Act claims, which could introduce legal uncertainties impacting the stock's performance.

13.03.2026 - NTLA Stock was up 5.9%

• Intellia Therapeutics (NTLA) saw a significant increase of 14.2% in its stock price today.
• The rise in stock price is linked to the FDA lifting clinical holds on Intellia's MAGNITUDE trials, which has provided regulatory clarity and bolstered investor confidence.
• An analyst upgrade from Jones Trading further boosted optimism about Intellia, emphasizing the potential of its gene editing programs for conditions like ATTR amyloidosis and HAE.
• The market is reflecting expectations for future growth for Intellia, as evidenced by its high Price/Sales ratio, indicating positive outlook on the company's prospects in the gene editing industry.

02.02.2026 - NTLA Stock was up 5.6%

• Intellia Therapeutics observed a significant uptrend in trading today, driven by a variety of positive developments:
• The company posted strong Q4 2025 earnings and revenue, surpassing expectations and demonstrating robust financial performance.
• Analysts at Chardan Capital reiterated a "Buy" rating with a target price of $26, showcasing confidence in the company's growth trajectory.
• Investor optimism has been fueled by Intellia's focus on its lonvo-z candidate for HAE, with upcoming Phase 3 data and a BLA submission.
• The FDA's removal of the clinical hold on Intellia's MAGNITUDE-2 trial for its gene-editing programs has further bolstered positive sentiment surrounding the stock.

11.02.2026 - NTLA Stock was down 7.9%

• Despite promising long-term data for its HAE candidate and FDA approval for its ATTR-CM therapy, concerns persist among investors regarding ongoing losses, liver safety issues, and lengthy path to profitability.
• The participation in the Leerink Global Healthcare Conference could give the company a chance to address investor worries and clarify its strategic outlook.
• The stock price surge following the FDA's removal of clinical holds on its gene-editing drug nex-z reflects investor confidence, although safety concerns and high costs of gene-editing therapies remain.
• NTLA is deemed undervalued compared to its fair value estimate, indicating that investors, despite recent positive developments, are still wary of potential clinical hurdles or slow therapy adoption that could impact future performance.